

ASST. COMMISSIONER FOR
PATENTS
Washington, D.C. 20231

Docket No.: P-IX 2405

Sir:

Transmitted herewith for filing is the patent application of
Inventor(s): William D. Huse
For: ANTI- $\alpha\beta$, RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND
METHODS OF USE

Enclosed are:

- ☒ 5 sheets of drawing(s).
☐ An assignment of the invention to _____
☐ A combination declaration and power of attorney.
☐ A verified statement to establish small entity status under 37 C.F.R. 1.9
 and 37 C.F.R. 1.27.
☒ Sequence disk in computer readable form.
☒ Statement under 37 C.F.R. § 1.821(f)
☒ Request for Filing Application Under 37 CFR 53(a), (b) & (d).

The filing fee has been calculated as shown below:

	Number Filed		Number Extra		Rate			Fee	
					Small Entity	Other Entity		Small Entity	Other Entity
Total Claims	25 - 20	=	5	x	\$11	\$22	=	\$	\$
Independent Claims	9 - 3	=	6	x	\$40	\$80	=	\$	\$
Multiple Dependent Claims Presented: _____ Yes _____ X No					\$130	\$260		\$	\$
					BASIC FEE			\$385	\$770
					TOTAL FEE			\$	\$

- Please charge my Deposit Account No. _____ the amount of \$_____. A duplicate copy of this sheet is enclosed.
- ☒ The payment of the filing fee is to be deferred until the Declaration is filed. Do not charge our deposit account.
- A check in the amount of \$_____ to cover the filing fee is enclosed.
- The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- Any additional filing fees required under 37 C.F.R. 1.16.
 — Any patent application processing fees under 37 C.F.R. 1.17.
- The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.
- Any patent application processing fees under 37 C.F.R. 1.17.
 — The issue fee set in 37 C.F.R. 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).
 — Any filing fees under 37 C.F.R. 1.16 for presentation of extra claims.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER 18836952847US

DATE OF DEPOSIT: JANUARY 30, 1997
 I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED
 WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST
 OFFICE TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE
 DATE INDICATED ABOVE AND IS ADDRESSED TO: THE ASSISTANT
 COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Matthew Eary
 (TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Respectfully submitted,

David A. Gay
 Registration No. 39,200
 CAMPBELL & FLORES LLP
 4370 La Jolla Village Drive
 Suite 700
 San Diego, California 92122

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REQUEST FOR FILING APPLICATION UNDER 37 CFR 1.53(a), (b) & (d)

The Asst. Commissioner for Patents
Washington, D.C. 20231

Ref. No. P-IX 2405

Sir:

This is a Request for filing a new patent application entitled:
ANTI- $\alpha_v\beta_3$ RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING
SAME AND METHODS OF USE

without an Assignment or Oath/Declaration but for which is
enclosed the following:

- [X] Cover Page;
[X] Abstract 1 page(s);
[X] 63 pages of Specification (only spec. and claims);
[] Specification in non-English language;
[X] 25 numbered claim(s); and
[] 5 sheet(s) of drawings [X] informal; [] formal;
size: [X] A4 [] 14" [] 11"
[] Verified Statement claiming Small Entity Status
(37 CFR 1.9(f) and 1.27(d))
- [] This application is a [] Continuation [] Divisional
[] Continuation-in-part of application serial no.
 filed .
- [] This application is based on, and claims the benefit of,
U.S. Provisional Application No. 60/ (yet to be
assigned), filed , which was converted from U.S.
Serial No. , and entitled .

This application is made by the following named inventor(s):

- Inventor: William D. Huse
Citizenship: United States
Residence: Del Mar, California
Post Office Address: 471 Avenida Primavera
Del Mar, California 92014

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER **TB836952347US**

DATE OF DEPOSIT: **JANUARY 30, 1997**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST
OFFICE 10 ADDRESSES" SERVICE UNDER 37 C.F.R. 1.10 ON THE
DATE INDICATED ABOVE, AND IS ADDRESSED TO: THE ASSISTANT
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Matthew Ray
(TYPED OR PRINTED NAME OR PERSON MAILING PAPER OR FEE)

Matthew Ray
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Respectfully submitted,

David A. Gay
David A. Gay
Registration No. 39,200
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122
(619) 535-9001



08/790540

PATENT

Our Docket: P-IX 2405

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
William D. Huse)

Serial No.: Unknown)

Filed: Herewith)

For: ANTI- α , β , RECOMBINANT)
HUMAN ANTIBODIES, NUCLEIC)
ACIDS ENCODING SAME AND)
METHODS OF USE)

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER 1583695234115

DATE OF DEPOSIT JANUARY 30, 1997
I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST
OFFICE TO ADDRESSEE" SERVICE UNDER 37 C.F.R. 1.10 ON THE
DATE INDICATED ABOVE. P.O. IS ADVISED TO THE ASSISTANT
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.

Matthew Egan
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)

Matthew Egan
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

BOX PATENT APPLICATION
Asst. Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT UNDER 37 C.F.R. § 1.821(f)

I hereby state that the content of the paper and
computer readable copies of the Sequence Listing, submitted in
accordance with 37 CFR § 1.821(c) and (e), respectively, are the
same.

Respectfully submitted,

1-30-97
Date

David A. Gay
David A. Gay
Registration No. 39,200
Telephone: (619) 535-9001
Facsimile: (619) 535-8949

CAMPBELL AND FLORES
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122



A P P L I C A T I O N

for

UNITED STATES LETTERS PATENT

on

ANTI- $\alpha_v\beta_3$ RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS
ENCODING SAME AND METHODS OF USE

by

William D. Huse

Sheets of Drawings: 5

Docket No.: P-IX 2405

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"EXPRESS MAIL" MAILING LABEL NUMBER **TB836952347US**

DATE OF DEPOSIT **JANUARY 30, 1997**

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
UNDER 37 C.F.R. 1.10 ON THE DATE INDICATED ABOVE,
AND IS ADDRESSED TO: THE ASSISTANT COMMISSIONER
FOR PATENTS, WASHINGTON, D.C. 20231

Matthew Fory
(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR FEE)
Matthew Fory
(SIGNATURE OF PERSON MAILING PAPER OR FEE)

Attorneys
CAMPBELL AND FLORES
4370 La Jolla Village Drive, Suite 700
San Diego, California 92122

5

9/ 08/79 0540

ANTI- $\alpha_v\beta_3$, RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS
ENCODING SAME AND METHODS OF USE

BACKGROUND OF THE INVENTION

The present invention relates generally to
5 integrin mediated diseases and, more particularly, to
nucleic acids encoding $\alpha_v\beta_3$ -inhibitory monoclonal
antibodies and to CDR grafted $\alpha_v\beta_3$ -inhibitory antibodies
for the therapeutic treatment of $\alpha_v\beta_3$ -mediated diseases.

Integrins are a class of cell adhesion
10 receptors that mediate both cell-cell and cell-
extracellular matrix adhesion events. Integrins consist
of heterodimeric polypeptides where a single α chain
polypeptide noncovalently associates with a single β
chain. There are now about 14 distinct α chain
15 polypeptides and at least about 8 different β chain
polypeptides which constitute the integrin family of cell
adhesion receptors. In general, different binding
specificities and tissue distributions are derived from
unique combinations of the α and β chain polypeptides or
20 integrin subunits. The family to which a particular
integrin is associated with is usually characterized by
the β subunit. However, the ligand binding activity of
the integrin is largely influenced by the α subunit. For
example, vitronectin binding integrins contain the α_v
25 integrin subunit.

It is now known that the vitronectin binding
integrins consist of at least three different α_v
containing integrins. These α_v containing integrins

include $\alpha_v\beta_3$, $\alpha_v\beta_1$ and $\alpha_v\beta_5$, all of which exhibit different ligand binding specificities. For example, in addition to vitronectin, $\alpha_v\beta_3$ binds to a large variety of extracellular matrix proteins including fibronectin, 5 fibrinogen, laminin, thrombospondin, von Willebrand factor, collagen, osteospondin and bone sialoprotein I. The integrin $\alpha_v\beta_1$ binds to fibronectin, osteopontin and vitronectin whereas $\alpha_v\beta_5$ is known to bind to vitronectin and osteopontin.

10 As cell adhesion receptors, integrins are involved in a variety of physiological processes including, for example, cell attachment, cell migration and cell proliferation. Different integrins play different roles in each of these biological processes and 15 the inappropriate regulation of their function or activity can lead to various pathological conditions. For example, inappropriate endothelial cell proliferation during neovascularization of a tumor has been found to be mediated by cells expressing vitronectin binding 20 integrins. In this regard, the inhibition of the vitronectin-binding integrin $\alpha_v\beta_3$ also inhibits this process of tumor neovascularization. By this same criteria, $\alpha_v\beta_3$ has also been shown to mediate the abnormal cell proliferation associated with restenosis and 25 granulation tissue development in cutaneous wounds, for example. Additional diseases or pathological states mediated or influenced by $\alpha_v\beta_3$ include, for example, metastasis, osteoporosis, age-related macular degeneration and diabetic retinopathy, and inflammatory 30 diseases such as rheumatoid arthritis and psoriasis.

Thus, agents which can specifically inhibit vitronectin-binding integrins would be valuable for the therapeutic treatment of diseases.

Many integrins mediate their cell adhesive
5 functions by recognizing the tripeptide sequence Arg-Gly-Asp (RGD) found within a large number of extracellular matrix proteins. A variety of approaches have attempted to model agents after this sequence to target a particular integrin-mediated pathology. Such approaches
10 include, for example, the use of RGD-containing peptides and peptide analogues which rely on specificity to be conferred by the sequences flanking the RGD core tripeptide sequence. Although there has been some limited success, most RGD-based inhibitors have been
15 shown to be, at most, selective for the targeted integrin and therefore exhibit some cross-reactivity to other non-targeted integrins. Such cross-reactive inhibitors therefore lack the specificity required for use as an efficacious therapeutic. This is particularly true for
20 previously identified inhibitors of the integrin $\alpha_v\beta_3$.

Monoclonal antibodies on the other hand exhibit the specificity required to be used as an effective therapeutic. Antibodies also have the advantage in that they can be routinely generated against essentially any
25 desired antigen. Moreover, with the development of combinatorial libraries, antibodies can now be produced faster and more efficiently than by previously used methods within the art. The use of combinatorial methodology also allows for the selection of the desired

antibody along with the simultaneous isolation of the encoding heavy and light chain nucleic acids. Thus, further modification can be performed to the combinatorial antibody without the incorporation of an additional cloning step.

Regardless of the potential advantages associated with the use of monoclonal antibodies as therapeutics, these molecules nevertheless have the drawback in that they are almost exclusively derived from non-human mammalian organisms. Therefore, their use as therapeutics is limited by the fact that they will normally elicit a host immune response. Methods for substituting the antigen binding site or complementarity determining regions (CDRs) of the non-human antibody into a human framework have been described. Such methods vary in terms of which amino acid residues should be substituted as the CDR as well as which framework residues should be changed to maintain binding specificity. In this regard, it is understood that proper orientation of the β sheet architecture, correct packing of the heavy and light chain interface and appropriate conformation of the CDRs are all important for preserving antigen specificity and affinity within the grafted antibody. However, all of these methods require knowledge of the nucleotide and amino acid sequence of the non-human antibody and the availability of an appropriately modeled human framework.

Thus, there exists a need for the availability of nucleic acids encoding integrin inhibitory antibodies

which can be used as compatible therapeutics in humans. For $\alpha_v\beta_3$ -mediated diseases, the present invention satisfies this need and provides related advantages as well.

5

SUMMARY OF THE INVENTION

The invention provides a LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$. The LM609 grafted antibody consists of at least one LM609 CDR grafted heavy chain polypeptide and at least one LM609 CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of $\alpha_v\beta_3$. The method consists of contacting $\alpha_v\beta_3$ with a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$. Finally, the invention provides for a method of treating an $\alpha_v\beta_3$ -mediated disease. The method consists of administering an effective amount of a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$.

25

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the nucleotide and deduced amino acid sequence of the variable region of the LM609 grafted

antibody. Figure 1A shows the nucleotide and deduced amino acid sequences for the LM609 grafted heavy chain variable region (Gln1-Ser117; SEQ ID NOS:1 and 2, respectively) while Figure 1B shows the nucleotide and deduced amino acid sequences for the LM609 grafted light chain variable region (Glu1-Lys107; SEQ ID NOS:3 and 4, respectively).

Figure 2 shows the nucleotide and deduced amino acid sequence of the variable region of the monoclonal antibody LM609. Figure 2A shows the nucleotide and deduced amino acid sequence of the LM609 heavy chain variable region (SEQ ID NOS:5 and 6, respectively). The variable region extends from amino acid Glu1 to Ala117. Figure 2B shows the nucleotide and deduced amino acid sequence of the LM609 light chain variable region (SEQ ID NOS:7 and 8, respectively). The variable region of the light chain extends from amino acid Asp1 to Lys107.

Figure 3 shows the competitive inhibition of LM609 IgG binding to the integrin $\alpha_v\beta_3$ with recombinant LM609 Fab. Soluble recombinant murine LM609 Fab fragments were prepared from periplasmic fractions of M13 bacteriophage clones muLM609M13 12 and muLM609M13 29. The periplasm samples were serially diluted, mixed with either 1 ng/ml, 5 ng/ml, or 50 ng/ml of LM609 IgG and then incubated in 96 well plates coated with purified $\alpha_v\beta_3$. Plates were washed and bound LM609 IgG detected with goat anti-murine Fc specific antibody conjugated to alkaline phosphatase. Fab produced by clone muLM609M13

12 inhibits both 1 ng/ml and 5 ng/ml LM609 IgG binding at all concentrations of Fab greater than 1:27 dilution.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to nucleic acids
5 encoding the monoclonal antibody (MAb) LM609. This antibody specifically recognizes the integrin $\alpha_v\beta_3$ and inhibits its functional activity. The invention is also directed to nucleic acids encoding and to polypeptides comprising non-murine forms of LM609 termed LM609 grafted
10 antibodies. A LM609 grafted antibody retains the binding specificity and inhibitory activity of its parent murine antibody LM609.

In one embodiment, the hybridoma expressing LM609 was used as a source to generate and clone cDNAs
15 encoding LM609. The heavy and light chain encoding cDNAs were sequenced and their CDR regions as defined by Kabat et al., *supra* were substituted into a human antibody framework to generate the non-murine form of the antibody. As an antibody having CDRs grafted to a human
20 acceptor framework, it is unlikely that LM609 grafted antibodies will elicit a host immune response and can therefore be advantageously used for the treatment of $\alpha_v\beta_3$ -mediated diseases.

As used herein, the term "monoclonal antibody
25 LM609" or "LM609" is intended to mean the murine monoclonal antibody specific for the integrin $\alpha_v\beta_3$, which is described by Cheresch, D.A. Proc. Natl. Acad. Sci. USA

84:6471-6475 (1987) and by Cheresch and Spiro J. Biol. Chem. 262:17703-17711 (1987). LM609 was produced against and is reactive with the M21 cell adhesion receptor now known as the integrin $\alpha_v\beta_3$. LM609 inhibits the attachment of M21 cells to $\alpha_v\beta_3$ ligands such as vitronectin, fibrinogen and von Willebrand factor (Cheresch and Spiro, *supra*) and is also an inhibitor of $\alpha_v\beta_3$ -mediated pathologies such as tumor induced angiogenesis (Brooks et al. Cell 79:1157-1164 (1994), granulation tissue development in cutaneous wound (Clark et al., Am. J. Pathology, 148:1407-1421 (1996)) and smooth muscle cell migration such as that occurring during restenosis (Choi et al., J. Vascular Surg., 19:125-134 (1994); Jones et al., Proc. Natl. Acad. Sci. 93:2482-2487 (1996)).

As used herein, the term "LM609 grafted antibody" is intended to refer to a non-mouse antibody or functional fragment thereof having substantially the same heavy and light chain CDR amino acid sequences as found in LM609 and absent of the substitution of LM609 amino acid residues outside of the CDRs as defined by Kabat et al., U.S. Dept. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983). The term "LM609 grafted antibody" or "LM609 grafted" when used in reference to heavy or light chain polypeptides is intended to refer to a non-mouse heavy or light chain or functional fragment thereof having substantially the same heavy or light chain CDR amino acid sequences as found in the heavy or light chain of LM609, respectively, and also absent of the substitution of LM609 residues outside of the CDRs as defined by Kabat et al., *supra*. When used in

reference to a functional fragment, not all LM609 CDRs need to be represented. Rather, only those CDRs that would normally be present in the antibody portion that corresponds to the functional fragment are intended to be
5 referenced as the LM609 CDR amino acid sequences in the LM609 grafted functional fragment. Similarly, the term "LM609 grafted antibody" or "LM609 grafted" used in reference to an encoding nucleic acid is intended to refer to a nucleic acid encoding a non-mouse antibody or
10 functional fragment being absent of the substitution of LM609 amino acids outside of the CDRs as defined by Kabat et al., *supra* and having substantially the same nucleotide sequence as the heavy and light chain CDR nucleotide sequences and encoding substantially the same
15 CDR amino acid sequences as found in LM609 and as defined by Kabat et al., *supra*.

The term "grafted antibody" or "grafted" when used in reference to heavy or light chain polypeptides or functional fragments thereof is intended to refer to a
20 heavy or light chain or functional fragment thereof having substantially the same heavy or light chain of a donor antibody, respectively, and also absent of the substitution of donor amino acid residues outside of the CDRs as defined by Kabat et al., *supra*. When used in
25 reference to a functional fragment, not all donor CDRs need to be represented. Rather, only those CDRs that would normally be present in the antibody portion that corresponds to the functional fragment are intended to be referenced as the donor CDR amino acid sequences in the
30 functional fragment. Similarly, the term "grafted

antibody" or "grafted" when used in reference to an encoding nucleic acid is intended to refer to a nucleic acid encoding an antibody or functional fragment, being absent of the substitution of donor amino acids outside
5 of the CDRs as defined by Kabat et al., *supra* and having substantially the same nucleotide sequence as the heavy and light chain CDR nucleotide sequences and encoding substantially the same CDR amino acid sequences as found in the donor antibody and as defined by Kabat et al.,
10 *supra*.

The meaning of the above terms are intended to include minor variations and modifications of the antibody so long as its function remains uncompromised. Functional fragments such as Fab, F(ab)₂, Fv, single chain
15 Fv (scFv) and the like are similarly included within the definition of the terms LM609 and LM609 grafted antibody. Such functional fragments are well known to those skilled in the art. Accordingly, the use of these terms in describing functional fragments of LM609 or LM609 grafted
20 antibodies are intended to correspond to the definitions well known to those skilled in the art. Such terms are described in, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New York (1989); Molec. Biology and Biotechnology: A
25 Comprehensive Desk Reference (Myers, R.A. (ed.), New York: VCH Publisher, Inc.); Huston et al., Cell Biophysics, 22:189-224 (1993); Plückthun and Skerra, Meth. Enzymol., 178:497-515 (1989) and in Day, E.D., Advanced Immunochemistry, Second Ed., Wiley-Liss, Inc.,
30 New York, NY (1990).

As with the above terms used for describing functional fragments of LM609 and a LM609 grafted antibody, the use of terms which reference other LM609, or LM609 grafted antibody domains, functional fragments, regions, nucleotide and amino acid sequences and polypeptides or peptides, is similarly intended to fall within the scope of the meaning of each term as it is known and used within the art. Such terms include, for example, "heavy chain polypeptide" or "heavy chain", "light chain polypeptide" or "light chain", "heavy chain variable region" (V_H) and "light chain variable region" (V_L) as well as the term "complementarity determining region" (CDR).

In the case where there are two or more definitions of a term which is used and/or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless explicitly stated to the contrary. A specific example is the use of the term "CDR" to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides. This particular region has been described by Kabat et al., *supra*, and by Chothia et al., J. Mol. Biol. 196:901-917 (1987) and by MacCallum et al., J. Mol. Biol. 262:732-745 (1996) where the definitions include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of LM609, LM609 grafted antibodies or variants thereof is intended to be within the scope of the term as defined and used herein. The amino acid

residues which encompass the CDRs as defined by each of the above cited references are set forth below in Table 1 as a comparison.

Table 1: CDR Definitions

	<u>Kabat</u> ¹	<u>Chothia</u> ²	<u>MacCallum</u> ³
5			
V _H CDR1	31-35	26-32	30-35
V _H CDR2	50-65	53-55	47-58
V _H CDR3	95-102	96-101	93-101
V _L CDR1	24-34	26-32	30-36
10 V _L CDR2	50-56	50-52	46-55
V _L CDR3	89-97	91-96	89-96

¹ Residue numbering follows the nomenclature of Kabat et al., *supra*

² Residue numbering follows the nomenclature of Chothia et al., *supra*

³ Residue numbering follows the nomenclature of MacCallum et al., *supra*

As used herein, the term "substantially" or "substantially the same" when used in reference to a nucleotide or amino acid sequence is intended to mean that the nucleotide or amino acid sequence shows a considerable degree, amount or extent of sequence identity when compared to a reference sequence. Such considerable degree, amount or extent of sequence identity is further considered to be significant and meaningful and therefore exhibit characteristics which are definitively recognizable or known. Thus, a

08705040.01490

nucleotide sequence which is substantially the same nucleotide sequence as a heavy or light chain of LM609, or a LM609 grafted antibody including fragments thereof, refers to a sequence which exhibits characteristics that

5 are definitively known or recognizable as encoding or as being the amino acid sequence of LM609 or a LM609 grafted antibody. Minor modifications thereof are included so long as they are recognizable as a LM609 or a LM609 grafted antibody sequence. Similarly, an amino acid

10 sequence which is substantially the same amino acid sequence as a heavy or light chain of LM609 grafted antibody or functional fragment thereof, refers to a sequence which exhibits characteristics that are definitively known or recognizable as representing the

15 amino acid sequence of a LM609 grafted antibody and minor modifications thereof.

As used herein, the term "fragment" when used in reference to a nucleic acid encoding LM609 or a LM609 grafted antibody is intended to mean a nucleic acid

20 having substantially the same sequence as a portion of a nucleic acid encoding LM609 or a LM609 grafted antibody. The nucleic acid fragment is sufficient in length and sequence to selectively hybridize to a LM609 or a LM609 grafted antibody encoding nucleic acid or a nucleotide

25 sequence that is complementary to an LM609 or LM609 grafted antibody encoding nucleic acid. Therefore, fragment is intended to include primers for sequencing and polymerase chain reaction (PCR) as well as probes for nucleic acid blot or solution hybridization. The meaning

30 of the term is also intended to include regions of

nucleotide sequences that do not directly encode LM609 polypeptides such as the introns, and the untranslated region sequences of the LM609 encoding gene.

As used herein, the term "functional fragment" when used in reference to a LM609 grafted antibody or to heavy or light chain polypeptides thereof is intended to refer to a portion of a LM609 grafted antibody including heavy or light chain polypeptides which still retains some or all or the $\alpha_v\beta_3$ binding activity, $\alpha_v\beta_3$ binding specificity and/or integrin $\alpha_v\beta_3$ -inhibitory activity. Such functional fragments can include, for example, antibody functional fragments such as Fab, F(ab)₂, Fv, single chain Fv (scFv). Other functional fragments can include, for example, heavy or light chain polypeptides, variable region polypeptides or CDR polypeptides or portions thereof so long as such functional fragments retain binding activity, specificity or inhibitory activity. The term is also intended to include polypeptides encompassing, for example, modified forms of naturally occurring amino acids such as D-stereoisomers, non-naturally occurring amino acids, amino acid analogues and mimetics so long as such polypeptides retain functional activity as defined above.

The invention provides a nucleic acid encoding a heavy chain polypeptide for a LM609 grafted antibody or a functional fragment thereof. Also provided is a nucleic acid encoding a light chain polypeptide for a LM609 grafted antibody or a functional fragment thereof. The nucleic acids consist of substantially the same heavy

or light chain variable region nucleotide sequences as those shown in Figure 1A and 1B (SEQ ID NOS:1 and 3, respectively) or a fragment thereof.

A LM609 grafted antibody, including functional
5 fragments thereof, is a non-mouse antibody which exhibits substantially the same binding activity, binding specificity and inhibitory activity as LM609. The LM609 grafted antibody Fv fragments described herein are produced by functionally replacing CDRs as defined by
10 Kabat et al., hereinafter referred to as "Kabat CDRs," within human heavy and light chain variable region polypeptides with the Kabat CDRs derived from LM609. Functional replacement of the CDRs was performed by recombinant methods known to those skilled in the art.
15 Such methods are commonly referred to as CDR grafting and are the subject matter of U.S. Patent No. 5,225,539. Such methods can also be found described in "Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man," Clark, M. (ed.),
20 Nottingham, England: Academic Titles (1993).

Substitution of amino acid residues outside of the Kabat CDRs can additionally be performed to maintain or augment beneficial binding properties of LM609 grafted antibodies so long as such amino acid substitutions do
25 not correspond to a donor amino acid at that particular position. Such substitutions allow for the modulation of binding properties without imparting any mouse sequence characteristics onto the antibody outside of the Kabat CDRs. Although the production of such antibodies is

described herein with reference to LM609 grafted antibodies, the substitution of such non-donor amino acids outside of the Kabat CDRs can be utilized for the production of essentially any grafted antibody. The
5 production of LM609 grafted antibodies is described further below in Example II.

Briefly, LM609 nucleic acid fragments having substantially the same nucleotide and encoding substantially the same amino acid sequence of each of the
10 heavy and light chain CDRs were synthesized and substituted into each of the respective human chain encoding nucleic acids. Modifications were performed within the non-Kabat CDR framework region. These individual changes were made by generating a population
15 of Kabat CDR grafted heavy and light chain variable regions wherein all possible non-donor amino acid changes outside of the Kabat CDRs were represented and then selecting the appropriate antibody by screening the population for binding activity. This screen resulted in
20 the selection of the LM609 grafted antibodies described herein.

The nucleotide sequences of the LM609 grafted heavy and light chain variable regions are shown in Figures 1A and 1B, respectively. These sequences
25 correspond substantially to those that encode the heavy and light chain variable region polypeptides of a LM609 grafted antibody. These nucleic acids are intended to include both the sense and anti-sense strands of the LM609 grafted antibody encoding sequences. Single- and

double-stranded nucleic acids are similarly included as well as non-coding portions of the nucleic acid such as introns, 5'- and 3'-untranslated regions and regulatory sequences of the gene for example.

5 As shown in Figure 1A, the LM609 grafted heavy chain variable region polypeptide is encoded by a nucleic acid of about 351 nucleotides in length which begins at the amino terminal Gln1 residue of the variable region through to Ser117. This heavy chain variable region
10 encoding nucleic acid is joined to a human IgG1 constant region to yield a coding region of 1431 nucleotides which encodes a heavy chain polypeptide of 477 total amino acids. Shown in Figure 1B is the LM609 grafted light chain variable region polypeptide which is encoded by a
15 nucleic acid of about 321 nucleotides in length beginning at the amino terminal Glu1 residue of the variable region through to Lys107. This light chain variable region nucleic acid is joined to a human kappa construct region to yield a coding region of 642 nucleotides which code
20 for a light chain polypeptide of 214 total amino acids.

Minor modification of these nucleotide sequences are intended to be included as LM609 grafted heavy and light chain encoding nucleic acids and their functional fragments. Such minor modifications include,
25 for example, those which do not change the encoded amino acid sequence due to the degeneracy of the genetic code as well as those which result in only a conservative substitution of the encoded amino acid sequence. Conservative substitutions of encoded amino acids

include, for example, amino acids which belong within the following groups: (1) non-polar amino acids (Gly, Ala, Val, Leu, and Ile); (2) polar neutral amino acids (Cys, Met, Ser, Thr, Asn, and Gln); (3) polar acidic amino acids (Asp and Glu); (4) polar basic amino acids (Lys, Arg and His); and (5) aromatic amino acids (Phe, Trp, Tyr, and His). Other minor modifications are included within the nucleic acids encoding LM609 grafted heavy and light chain polypeptides so long as the nucleic acid or encoded polypeptides retain some or all of their function as described herein.

Thus, the invention also provides a nucleic acid encoding a LM609 grafted heavy chain or functional fragment thereof wherein the nucleic acid encodes substantially the same LM609 grafted heavy chain variable region amino acid sequence as that shown in Figure 1A (SEQ ID NO:2) or a fragment thereof. Similarly, the invention also provides a nucleic acid encoding a LM609 grafted light chain or functional fragment thereof wherein the nucleic acid encodes substantially the same light chain variable region amino acid sequence as that shown in Figure 1B (SEQ ID NO:4) or a fragment thereof.

In addition to conservative substitutions of amino acids, minor modifications of the LM609 grafted antibody encoding nucleotide sequences which allow for the functional replacement of amino acids are also intended to be included within the definition of the term. The substitution of functionally equivalent amino acids encoded by the LM609 grafted antibody nucleotide

sequences is routine and can be accomplished by methods known to those skilled in the art. Briefly, the substitution of functionally equivalent amino acids can be made by identifying the amino acids which are desired to be changed, incorporating the changes into the encoding nucleic acid and then determining the function of the recombinantly expressed and modified LM609 grafted polypeptide or polypeptides. Rapid methods for making and screening multiple simultaneous changes are well known within the art and can be used to produce a library of encoding nucleic acids which contain all possible or all desired changes and then expressing and screening the library for LM609 grafted polypeptides which retain function. Such methods include, for example, codon based mutagenesis, random oligonucleotide synthesis and partially degenerate oligonucleotide synthesis.

Codon based mutagenesis is the subject matter of U.S. Patent Nos. 5,264,563 and 5,523,388 and is advantageous for the above procedures since it allows for the production of essentially any and all desired frequencies of encoded amino acid residues at any and all particular codon positions within an oligonucleotide. Such desired frequencies include, for example, the truly random incorporation of all twenty amino acids or a specified subset thereof as well as the incorporation of a predetermined bias of one or more particular amino acids so as to incorporate a higher or lower frequency of the biased residues compared to other incorporated amino acid residues. Random oligonucleotide synthesis and partially degenerate oligonucleotide synthesis can

similarly be used for producing and screening for functionally equivalent amino acid changes. However, due to the degeneracy of the genetic code, such methods will incorporate redundancies at a desired amino acid position. Random oligonucleotide synthesis is the coupling of all four nucleotides at each nucleotide position within a codon whereas partially degenerate oligonucleotide synthesis is the coupling of equal portions of all four nucleotides at the first two nucleotide positions, for example, and equal portions of two nucleotides at the third position. Both of these latter synthesis methods can be found described in, for example, Cwirla et al., Proc. Natl. Acad. Sci. USA 87:6378-6382, (1990) and Devlin et al., Science 249:404-406, (1990).

Identification of amino acids to be changed can be accomplished by those skilled in the art using current information available regarding the structure and function of antibodies as well as available and current information encompassing methods for CDR grafting procedures.

Using the above described methods known within the art, any or all of the non-identical amino acids can be changed either alone or in combination with amino acids at different positions to incorporate the desired number of amino acid substitutions at each of the desired positions. The LM609 grafted polypeptides containing the desired substituted amino acids are then produced and screened for retention or augmentation of function

compared to the unsubstituted LM609 grafted polypeptides. Production of the substituted LM609 grafted polypeptides can be accomplished by, for example, recombinant expression using methods known to those skilled in the art. Those LM609 grafted polypeptides which exhibit retention or augmentation of function compared to unsubstituted LM609 grafted polypeptides are considered to contain minor modifications of the encoding nucleotide sequence which result in the functional replacement of one or more amino acids.

The functional replacement of amino acids is beneficial when producing grafted antibodies having human framework sequences since it allows for the rapid identification of equivalent amino acid residues without the need for structural information or the laborious procedures necessary to assess and identify which amino acid residues should be considered for substitution in order to successfully transfer binding function from the donor. Moreover, it eliminates the actual step-wise procedures to change and test the amino acids identified for substitution. Essentially, using the functional replacement approach described above, all non-identical amino acid residues between the donor and the human framework can be identified and substituted with any or all other possible amino acid residues, excluding the corresponding donor amino acid, at each non-identical position to produce a population of substituted polypeptides containing all possible or all desired permutations and combinations. The population of substituted polypeptides can then be screened for those

substituted polypeptides which retain function. Using the codon based mutagenesis procedures described above, the generation of a library of substituted amino acid residues and the screening of functionally replaced residues has been used for the rapid production of grafted therapeutic antibodies as well as for the rapid alteration of antibody affinity. Such procedures are exemplified in, for example, Rosok et al., J. Biol. Chem. 271:22611-22618 (1996) and in Glaser et al., J. Immunol. 149:3903-3913 (1992), respectively.

The invention further provides fragments of LM609 grafted heavy and light chain encoding nucleic acids wherein such fragments consist substantially of the same nucleotide or amino acid sequence as the LM609 grafted variable region of the heavy or light chain polypeptides. The variable region of the heavy chain polypeptide consists essentially of nucleotides 1-351 and of amino acid residues Gln1 to Ser117 of Figure 1A (SEQ ID NOS:1 and 2, respectively). The variable region of the light chain polypeptide consists essentially of nucleotides 1-321 and of amino acid residues Glu1 to Lys107 of Figure 1B (SEQ ID NOS:3 and 4, respectively). The termini of such variable region encoding nucleic acids is not critical so long as the intended purpose and function remains the same.

Fragments additional to the variable region nucleic acid fragments are provided as well. Such fragments include, for example, nucleic acids consisting substantially of the same nucleotide sequence as a CDR of

a LM609 grafted heavy or light chain polypeptide. Sequences corresponding to the LM609 grafted CDRs include, for example, those regions defined by Kabat et al., *supra*, and/or those regions defined by Chothia et al., *supra*, as well as those defined by MacCallum et al., *supra*. The LM609 grafted CDR fragments for each of the above definitions correspond to the nucleotides set forth below in Table 2. The nucleotide sequence numbering is taken from the primary sequence shown in Figures 1A and 1B (SEQ ID NOS:1 and 3) and conforms to the definitions previously set forth in Table 1.

Table 2: LM609 Grafted CDR Nucleotide Residues

	<u>Kabat</u>	<u>Chothia</u>	<u>MacCallum</u>
V _H CDR1	91-105	76-96	88-105
15 V _H CDR2	148-198	157-168	139-177
V _H CDR3	295-318	298-315	289-315
V _L CDR1	70-102	76-96	88-108
V _L CDR2	148-168	148-156	136-165
V _L CDR3	265-291	271-288	265-288

Similarly, the LM609 grafted CDR fragments for each of the above definitions correspond to the amino acid residues set forth below in Table 3. The amino acid residue number is taken from the primary sequence shown in Figures 1A and 1B (SEQ ID NOS:2 and 4) and conforms to the definitions previously set forth in Table 1.

Table 3: LM609 Grafted CDR Amino Acid Residues

	<u>Kabat</u>	<u>Chothia</u>	<u>MacCallum</u>
V _H CDR1	Ser31-Ser35	Gly26-Tyr32	Ser30-Ser35
V _H CDR2	Lys50-Gly66	Ser53-Gly56	Trp47-Tyr59
5 V _H CDR3	His99-Tyr106	Asn100-Ala105	Ala97-Ala105
V _L CDR1	Gln24-His34	Ser26-His32	Ser30-Tyr36
V _L CDR2	Tyr50-Ser56	Tyr50-Ser52	Leu46-Ile55
V _L CDR3	Gln89-Thr97	Ser91-His96	Gln89-His96

Thus, the invention also provides nucleic acid
 10 fragments encoding substantially the same amino acid
 sequence as a CDR of a LM609 grafted heavy or light chain
 polypeptide.

Nucleic acids encoding LM609 grafted heavy and
 light chain polypeptides and fragments thereof are useful
 15 for a variety of diagnostic and therapeutic purposes.
 For example, the LM609 grafted nucleic acids can be used
 to produce LM609 grafted antibodies and functional
 fragments thereof having binding specificity and
 inhibitory activity against the integrin $\alpha_v\beta_3$. The
 20 antibody and functional fragments thereof can be used for
 the diagnosis or therapeutic treatment of $\alpha_v\beta_3$ -mediated
 disease. A LM609 grafted antibody and functional
 fragments thereof can be used, for example, to inhibit
 binding activity or other functional activities of $\alpha_v\beta_3$,
 25 that are necessary for progression of an $\alpha_v\beta_3$ -mediated
 disease. Other functional activities necessary for
 progression of $\alpha_v\beta_3$ -mediated disease include, for example,
 the activation of $\alpha_v\beta_3$, $\alpha_v\beta_3$ -mediated signal transduction

and the $\alpha_v\beta_3$ -mediated prevention of apoptosis. Advantageously, however, a LM609 grafted antibody comprises non-mouse framework amino acid sequences and as such is less antigenic in regard to the induction of a host immune response. The LM609 grafted antibody nucleic acids of the invention can also be used to model functional equivalents of the encoded heavy and light chain polypeptides.

Thus, the invention provides LM609 grafted heavy chain and LM609 grafted light chain polypeptides or functional fragments thereof. The LM609 grafted heavy chain polypeptide exhibits substantially the same amino acid sequence as that shown in Figure 1A (SEQ ID NO:2) or functional fragment thereof whereas the LM609 grafted light chain polypeptide exhibits substantially the same amino acid sequence as that shown in Figure 1B (SEQ ID NO:4) or functional fragment thereof. Also provided is a LM609 grafted antibody or functional fragment thereof. The antibody is generated from the above heavy and light chain polypeptides or functional fragments thereof and exhibits selective binding affinity to $\alpha_v\beta_3$.

The invention provides a nucleic acid encoding a heavy chain polypeptide for monoclonal antibody LM609 or functional fragment thereof. Also provided is a nucleic acid encoding a light chain polypeptide for monoclonal antibody LM609 or a functional fragment thereof. The nucleic acids consist of substantially the same heavy or light chain variable region nucleotide

sequences as that shown in Figure 2A and 2B (SEQ ID NOS:5 and 7, respectively) or a fragment thereof.

As described previously, monoclonal antibody LM609 has been shown in the art to have binding activity to the integrin $\alpha_v\beta_3$. Although specificity can in principle be generated towards essentially any target, LM609 is an integrin inhibitory antibody that exhibits substantial specificity and inhibitory activity to a single member within an integrin family. In this case, LM609 exhibits substantial specificity and inhibitory activity to the $\alpha_v\beta_3$ integrin within the β_3 family. The amino acid or nucleotide sequence of monoclonal antibody LM609 has never been previously isolated and characterized.

The isolation and characterization of LM609 encoding nucleic acids was performed by techniques known to those skilled in the art and which are described further below in the Examples. Briefly, cDNA from hybridoma LM609 was generated and used as the source for which to isolate LM609 encoding nucleic acids. Isolation was performed by first determining the N-terminal amino acid sequence for each of the heavy and light chain polypeptides and then amplifying by PCR the antibody encoding sequences from the cDNA. The 5' primers were reverse translated to correspond to the newly determined N-terminal amino acid sequences whereas the 3' primers corresponded to sequences substantially similar to antibody constant region sequences. Amplification and

cloning of the products resulted in the isolation of the nucleic acids encoding heavy and light chains of LM609.

The nucleotide sequences of the LM609 heavy and light chain variable region sequences are shown in Figure 2A and 2B, respectively. These sequences correspond substantially to those that encode the variable region heavy and light chain polypeptides of LM609. As with the LM609 grafted antibody nucleic acids, these LM609 nucleic acids are intended to include both sense and anti-sense strands of the LM609 encoding sequences. Single- and double-stranded nucleic acids are also included as well as non-coding portions of the nucleic acid such as introns, 5'- and 3'-untranslated regions and regulatory sequences of the gene for example.

15

As shown in Figure 2A, the LM609 heavy chain variable region polypeptide is encoded by a nucleic acid of about 351 nucleotides in length which begins at the amino terminal Glu1 residue of the variable region through to Ala 117. The murine LM609 antibody heavy chain has an IgG2a constant region. Shown in Figure 2B is the LM609 light chain variable region polypeptide which is encoded by a nucleic acid of about 321 nucleotides in length which begins at the amino terminal Asp1 residue of the variable region through to Lys 107. In the functional antibody, LM609 has a kappa light chain constant region.

As with the LM609 grafted antibody nucleic acids, minor modifications of these LM609 nucleotide sequences are intended to be included as heavy and light chain LM609 encoding nucleic acids. Such minor
5 modifications are included within the nucleic acids encoding LM609 heavy and light chain polypeptides so long as the nucleic acids or encoded polypeptides retain some or all of their function as described.

Thus, the invention also provides a nucleic
10 acid encoding a LM609 heavy chain or functional fragment wherein the nucleic acid encodes substantially the same variable region amino acid sequence of monoclonal antibody LM609 as that shown in Figure 2A (SEQ ID NO:6) or a fragment thereof. Similarly, the invention also
15 provides a nucleic acid encoding a LM609 light chain or functional fragment wherein the nucleic acid encodes substantially the same variable region amino acid sequence of monoclonal antibody LM609 as that shown in Figure 2B (SEQ ID NO:8) or a fragment thereof.

20 The invention further provides fragments of LM609 heavy and light chain encoding nucleic acids wherein such fragments consist substantially of the same nucleotide or amino acid sequence as the variable region of LM609 heavy or light chain polypeptides. The variable
25 region of the LM609 heavy chain polypeptide consists essentially of nucleotides 1-351 and of amino acid residues Glu1 to Ala117 of Figure 2A (SEQ ID NOS:5 and 6, respectively). The variable region of the LM609 light chain polypeptide consists essentially of nucleotides

1-321 and of amino acid residues Asp1 to lys107 of Figure 2B (SEQ ID NOS:7 and 8, respectively). The termini of such variable region encoding nucleic acids is not critical so long as the intended purpose and function remains the same. Such intended purposes and functions include, for example, use for the production of recombinant polypeptides or as hybridization probes for heavy and light chain variable region sequences.

Fragments additional to the variable region nucleic acid fragments are provided as well. Such fragments include, for example, nucleic acids consisting substantially of the same nucleotide sequence as a CDR of a LM609 heavy or light chain polypeptide. Sequences corresponding to the LM609 CDRs include, for example, those regions within the variable region which are defined by Kabat et al., *supra*, and/or those regions within the variable regions which are defined by Chothia et al., *supra*, as well as those regions defined by MacCallum et al., *supra*. The LM609 CDR fragments for each of the above definitions correspond to the nucleotides set forth below in Table 4. The nucleotide sequence numbering is taken from the primary sequence shown in Figures 2A and 2B (SEQ ID NOS:5 and 7) and conforms to the definitions previously set forth in Table 1.

Table 4: LM609 CDR Nucleotide Residues

	<u>Kabat</u>	<u>Chothia</u>	<u>MacCallum</u>
V _H CDR1	91-105	76-96	88-105
V _H CDR2	148-198	157-168	139-177
5 V _H CDR3	295-318	298-315	289-315
V _L CDR1	70-102	76-96	88-108
V _L CDR2	148-168	148-156	136-165
V _L CDR3	265-291	271-288	265-288

Similarly, the LM609 CDR fragments for each of
 10 the above definitions correspond to the amino acid
 residues set forth below in Table 5. The amino acid
 residue numbering is taken from the primary sequence
 shown in Figures 2A and 2B (SEQ ID NOS:6 and 8) and
 conforms to the definitions set forth in Table 1.

15 Table 5: LM609 CDR Amino Acid Residues

	<u>Kabat</u>	<u>Chothia</u>	<u>MacCallum</u>
V _H CDR1	Ser31-Ser35	Gly26-Tyr32	Ser30-Ser35
V _H CDR2	Lys50-Gly66	Ser53-Gly56	Trp47-Tyr59
V _H CDR3	His99-Tyr106	Asn100-Ala105	Ala97-Ala105
20 V _L CDR1	Gln24-His34	Ser26-His32	Ser30-Tyr36
V _L CDR2	Tyr50-Ser56	Tyr50-Ser52	Leu46-Ile55
V _L CDR3	Gln89-Thr97	Ser91-His96	Gln89-His96

Nucleic acids encoding LM609 heavy and light
 chain polypeptides and fragments thereof are useful for a
 25 variety of diagnostic and therapeutic purposes. For

example, the LM609 nucleic acids can be used to produce recombinant LM609 antibodies and functional fragments thereof having binding specificity and inhibitory activity against the integrin $\alpha_v\beta_3$. The antibody and
5 functional fragments thereof can be used to determine the presence or absence of $\alpha_v\beta_3$ in a sample to diagnose the susceptibility or occurrence of an $\alpha_v\beta_3$ -mediated disease. Alternatively, the recombinant LM609 antibodies and functional fragments thereof can be used for the
10 therapeutic treatment of $\alpha_v\beta_3$ -mediated diseases or pathological state. As with a LM609 grafted antibody, recombinant LM609 and functional fragments thereof can be used to inhibit the binding activity or other functional activities of $\alpha_v\beta_3$ that are necessary for progression of
15 the $\alpha_v\beta_3$ -mediated disease or pathological state.

The LM609 nucleic acids of the invention can also be used to model functional equivalents of the encoded heavy and light chain polypeptides. Such functional equivalents can include, for example,
20 synthetic analogues or mimics of the encoded polypeptides or functional fragments thereof. A specific example would include peptide mimetics of the LM609 CDRs that retain some or substantially the same binding or inhibitory activity of LM609. Additionally, the LM609
25 encoding nucleic acids can be used to engineer and produce nucleic acids which encode modified forms or derivatives of the antibody LM609, its heavy and light chain polypeptides and functional fragments thereof. As described previously, such modified forms or derivatives
30 include, for example, non-mouse antibodies, their

corresponding heavy and light chain polypeptides and functional fragments thereof which exhibit substantially the same binding and inhibitory activity as LM609.

The invention also provides a method of
5 treating an $\alpha_v\beta_3$ -mediated disease. The method consists of administering an effective amount of a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$. Also provided is a method of inhibiting a function of $\alpha_v\beta_3$. The method
10 consists of contacting $\alpha_v\beta_3$ with a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$.

As described previously, a LM609 grafted antibody is a monoclonal antibody which exhibits
15 essentially all of the binding characteristics as does its parental CDR-donor antibody LM609. These characteristics include, for example, significant binding specificity and affinity for the integrin $\alpha_v\beta_3$. The Examples below demonstrate these binding properties and
20 further show that the binding of such antibodies to $\alpha_v\beta_3$ inhibits $\alpha_v\beta_3$ ligand binding and function. Thus, LM609 grafted antibodies are useful for a large variety of diagnostic and therapeutic purposes directed to the inhibition of $\alpha_v\beta_3$ function.

25 The integrin $\alpha_v\beta_3$ functions in numerous cell adhesion and migration associated events. As such, the dysfunction or dysregulation of this integrin, its function, or of cells expressing this integrin, is

associated with a large number of diseases and pathological conditions. The inhibition $\alpha_v\beta_3$ binding or function can therefore be used to treat or reduce the severity of such $\alpha_v\beta_3$ -mediated pathological conditions.

- 5 Described below are examples of several pathological conditions mediated by $\alpha_v\beta_3$, since the inhibition of at least this integrin reduces the severity of the condition. These examples are intended to be representative and as such are not inclusive of all
- 10 $\alpha_v\beta_3$ -mediated diseases. For example, there are numerous pathological conditions additional to those discussed below which exhibit the dysregulation of $\alpha_v\beta_3$ binding, function or the dysregulation of cells expressing this integrin and in which the pathological condition can be
- 15 reduced, or will be found to be reduced, by inhibiting the binding $\alpha_v\beta_3$. Such pathological conditions which exhibit this criteria, are intended to be included within the definition of the term as used herein.

- Angiogenesis, or neovascularization, is the
- 20 process where new blood vessels form from pre-existing vessels within a tissue. As described further below, this process is mediated by endothelial cells expressing $\alpha_v\beta_3$ and inhibition of at least this integrin, inhibits new vessel growth. There are a variety of pathological
- 25 conditions that require new blood vessel formation or tissue neovascularization and inhibition of this process inhibits the pathological condition. As such, pathological conditions that require neovascularization for growth or maintenance are considered to be
- 30 $\alpha_v\beta_3$ -mediated diseases. The extent of treatment, or

reduction in severity, of these diseases will therefore depend on the extent of inhibition of neovascularization. These $\alpha_v\beta_3$ -mediated diseases include, for example, inflammatory disorders such as immune and non-immune

5 inflammation, chronic articular rheumatism, psoriasis, disorders associated with inappropriate or inopportune invasion of vessels such as diabetic retinopathy, neovascular glaucoma and capillary proliferation in atherosclerotic plaques as well as cancer disorders.

10 Such cancer disorders can include, for example, solid tumors, tumor metastasis, angiofibromas, retrolental, fibroplasia, hemangiomas, Kaposi's sarcoma and other cancers which require neovascularization to support tumor growth. Additional diseases which are considered

15 angiogenic include psoriasis and rheumatoid arthritis as well as retinal diseases such as macular degeneration. Diseases other than those requiring new blood vessels which are $\alpha_v\beta_3$ -mediated diseases include, for example, restenosis and osteoporosis.

20 Treatment of the $\alpha_v\beta_3$ -mediated diseases can be performed by administering an effective amount of a LM609 grafted antibody or a functional fragment thereof so as to bind to $\alpha_v\beta_3$ and inhibit its function. Administration can be performed using a variety of methods known in the

25 art. The choice of method will depend on the specific $\alpha_v\beta_3$ -mediated disease and can include, for example, the *in vivo*, *in situ* and *ex vivo* administration of a LM609 grafted antibody or functional fragment thereof, to cells, tissues, organs, and organisms. Moreover, such

30 antibodies or functional fragments can be administered to

an individual exhibiting or at risk of exhibiting an $\alpha_v\beta_3$ -mediated disease. Definite clinical diagnosis of an $\alpha_v\beta_3$ -mediated disease warrants the administration of a LM609 grafted antibody or a functional fragment thereof.

- 5 Prophylactic applications are warranted in diseases where the $\alpha_v\beta_3$ -mediated disease mechanisms precede the onset of overt clinical disease. Thus, individuals with familial history of disease and predicted to be at risk by reliable prognostic indicators can be treated
- 10 prophylactically to interdict $\alpha_v\beta_3$ -mediated mechanisms prior to their onset.

- LM609 grafted antibody or functional fragments thereof can be administered in a variety of formulations and pharmaceutically acceptable media for the effective
- 15 treatment or reduction in the severity of an $\alpha_v\beta_3$ -mediated disease. Such formulations and pharmaceutically acceptable medias are well known to those skilled in the art. Additionally, a LM609 grafted antibody or functional fragments thereof can be administered with
- 20 other compositions which can enhance or supplement the treatment or reduction in severity of an $\alpha_v\beta_3$ -mediated disease. For example, the coadministration of a LM609 grafted antibody to inhibit tumor-induced neovascularization and a chemotherapeutic drug to
- 25 directly inhibit tumor growth is one specific case where the administration of other compositions can enhance or supplement the treatment of an $\alpha_v\beta_3$ -mediated disease.

A LM609 grafted antibody or functional fragments are administered by conventional methods, in dosages which are sufficient to cause the inhibition of $\alpha_v\beta_3$ integrin binding at the sight of the pathology.

- 5 Inhibition can be measured by a variety of methods known in the art such as *in situ* immunohistochemistry for the prevalence of $\alpha_v\beta_3$ containing cells at the site of the pathology as well as include, for example, the observed reduction in the severity of the symptoms of the
- 10 $\alpha_v\beta_3$ -mediated disease.

- In vivo* modes of administration can include intraperitoneal, intravenous and subcutaneous administration of a LM609 grafted antibody or a functional fragment thereof. Dosages for antibody
- 15 therapeutics are known or can be routinely determined by those skilled in the art. For example, such dosages are typically administered so as to achieve a plasma concentration from about 0.01 $\mu\text{g/ml}$ to about 100 $\mu\text{g/ml}$, preferably about 1-5 $\mu\text{g/ml}$ and more preferably about 5
- 20 $\mu\text{g/ml}$. In terms of amount per body weight, these dosages typically correspond to about 0.1-300 mg/kg, preferably about 0.2-200 mg/kg and more preferably about 0.5-20 mg/kg. Depending on the need, dosages can be
- 25 administered once or multiple times over the course of the treatment. Generally, the dosage will vary with the age, condition, sex and extent of the $\alpha_v\beta_3$ -mediated pathology of the subject and should not be so high as to cause adverse side effects. Moreover, dosages can also be modulated by the physician during the course of the
- 30 treatment to either enhance the treatment or reduce the

potential development of side effects. Such procedures are known and routinely performed by those skilled in the art.

The specificity and inhibitory activity of
5 LM609 grafted antibodies and functional fragments thereof allow for the therapeutic treatment of numerous $\alpha_v\beta_3$ -mediated diseases. Such diseases include, for example, pathological conditions requiring neovascularization such as tumor growth, and psoriasis as
10 well as those directly mediated by $\alpha_v\beta_3$, such as restenosis and osteoporosis. Thus, the invention provides methods and LM609 grafted antibody containing compositions for the treatment of such diseases.

Throughout this application various
15 publications are referenced within parentheses. The disclosures of these publications in their entireties are hereby incorporated by reference in this application in order to more fully describe the state of the art to which this invention pertains.

20 It is understood that modifications which do not substantially affect the activity of the various embodiments of this invention are also included within the definition of the invention provided herein. Accordingly, the following examples are intended to
25 illustrate but not limit the present invention.

EXAMPLE I**Isolation and Characterization of LM609****Encoding Nucleic Acids**

This Example shows the cloning and sequence
5 determination of LM609 encoding nucleic acids.

LM609 is directed against the human vitronectin
receptor, integrin $\alpha_v\beta_3$. $\alpha_v\beta_3$ is highly upregulated in
melanoma, glioblastoma, and mammary carcinoma and plays a
role in the proliferation of M21 melanoma cells both in
10 vitro and in vivo. $\alpha_v\beta_3$ also plays a role in
angiogenesis, restenosis and the formation of granulation
tissue in cutaneous wounds. LM609 has been shown to
inhibit the adhesion of M21 cells to vitronectin as well
as prevent proliferation of M21 cells in vitro. Thus,
15 grafting of LM609 could result in a clinically valuable
therapeutic agent.

cDNA Synthesis of LM609 Variable Regions: For
cDNA synthesis, total RNA was prepared from 10^8 LM609
hybridoma cells using a modification of the method
20 described by Chomczynski and Sacchi (Chomczynski and
Sacchi, *Analyt. Biochem.* 162:156 (1987)). LM609 variable
(V) region genes were cloned by reverse
transcription-polymerase chain reaction (RT-PCR) and cDNA
was synthesized using BRL Superscript kit. Briefly, 5 μ g
25 of total cellular RNA, 650 ng oligo dT and H_2O were
brought to a total volume of 55 μ l. The sample was
heated to 70°C for 10 min and chilled on ice. Reaction
buffer was added and the mixture brought to 10 mM DTT and

1 mM dNTPs and heated at 37°C for 2 minutes. 5 μ l (1000 units) reverse transcriptase was added and incubated at 37°C for 1 hour and then chilled on ice.

All oligonucleotides were synthesized by
 5 β -cyanoethyl phosphoramidite chemistry on an ABI 394 DNA synthesizer. Oligonucleotides used for PCR amplification and routine site-directed mutagenesis were purified using oligonucleotide purification cartridges (Applied Biosystems, Foster City, CA). Forward PCR primers were
 10 designed from N-terminal protein sequence data generated from purified LM609 antibody. The forward PCR primers contained sequences coding for the first six amino acids in each antibody variable chain (protein sequenced at San Diego State University). The sequence of the light chain
 15 forward PCR primer (997) was 5'-GCC CAA CCA GCC ATG GCC GAT ATT GTG CTA ACT CAG-3' (SEQ ID NO:19) whereas the light chain reverse PCR primer (734) was 5'-AC AGT TGG TGC AGC ATC AGC-3' (SEQ ID NO:20) used. This reverse primer corresponds to mouse light chain kappa amino acid
 20 residues 109-115. The sequence of the heavy chain forward PCR primer (998) was 5'-ACC CCT GTG GCA AAA GCC GAA GTG CAG CTG GTG GAG-3' (SEQ ID NO:21). Heavy chain reverse PCR primer 733: 5'-GA TGG GGG TGT CGT TTT GGC-3' (SEQ ID NO:22). The PCR primers also contain regions of
 25 homology with specific sequences within the immunoexpression vector.

V_L and V_H chains were amplified in two separate 50 μ l reaction mixtures containing 2 μ l of the cDNA-RNA heteroduplex, 66.6 mM Tris-HCl pH 8.8, 1.5 mM $MgCl_2$, 0.2

mM of each four dNTPs, 10 mM 2-mercaptoethanol, 0.25
 units Taq polymerase (Boehringer-Mannheim, Indianapolis,
 IN) and 50 pmoles each of primers 997 and 734 and 998 and
 733, respectively. The mixtures were overlaid with
 5 mineral oil and cycled for two rounds of PCR with each
 cycle consisting of 30 seconds at 94°C (denature), 30
 seconds at 50°C (anneal), and 30 seconds at 72°C
 (synthesis). This reaction was immediately followed by
 30 cycles of PCR consisting of 30 seconds at 94°C
 10 (denature), 30 seconds at 55°C (anneal), and 30 seconds at
 72°C (synthesis) followed by a final synthesis reaction
 for 5 minutes at 72°C. The reaction products were pooled,
 extracted with CHCl₃ and ethanol precipitated.

Amplified products were resuspended in 20 µl TE
 15 buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0) and
 electrophoresed on a 5% polyacrylamide gel. Bands
 migrating at expected molecular weights of V_H and V_L were
 excised, chemically eluted from the gel slice, extracted
 with organic solvents and ethanol precipitated.

20 Cloning of amplified V_H and V_L genes into M13
 phage immunoexpression vector: The amplified V region
 gene products were sequentially cloned into the phage
 immunoexpression vector by hybridization mutagenesis
 (Near, R. *Biotechniques* 12:88 (1992); Yelton et al., *J.*
 25 *Immunol.* 155:1994-2003 (1995)). Introduction of the
 amplified V_L and V_H sequences by hybridization mutagenesis
 positions the antibody sequences in frame with the
 regulatory elements contained in the M13 vector required
 for efficient Fab expression. One advantage of this

technique is that no restriction endonuclease sites need to be incorporated into the V_L or V_H gene sequences for cloning as is done with conventional DNA ligation methods.

- 5 To perform the cloning, 400 ng each of the double-stranded amplified products were first phosphorylated with polynucleotide kinase. 100 ng of the phosphorylated LM609 V_L product was mixed with 250 ng of uridinylated BS11 phage immunoexpression vector,
- 10 denatured by heating to 90°C and annealed by gradual cooling to room temperature. BS11 is an M13 immunoexpression vector derived from M13 IX and encodes CH_1 of murine IgG1 and murine kappa light chain constant domain (Huse, W.D. In: Antibody Engineering: A Practical
- 15 Guide, C.A.K. Borrebaeck, ed. W.H. Freeman and Co., Publishers, New York, pp. 103-120 (1991)). Nucleotide sequences included in the PCR amplification primers anneal to complementary sequences present in the single-stranded BS11 vector. The annealed mixture was fully
- 20 converted to a double-stranded molecule with T4 DNA polymerase plus dNTPs and ligated with T4 ligase. 1 μ l of the mutagenesis reaction was electroporated into *E. coli* strain DH10B, titered onto a lawn of XL-1 *E. coli* and incubated until plaques formed. Plaque lift assays
- 25 were performed as described using goat anti-murine kappa chain antibody conjugated to alkaline phosphatase (Yelton et al, *supra*; Huse, W.D., *supra*). Fifteen murine light chain positive M13 phage clones were isolated, pooled and used to prepare uridinylated vector to serve as template

for hybridization mutagenesis with the PCR amplified LM609 V_H product.

Clones expressing functional murine LM609 Fab were identified by binding to purified $\alpha_v\beta_3$ by ELISA.

- 5 Briefly, Immulon II ELISA plates were coated overnight with 1 $\mu\text{g/ml}$ (100 ng/well) $\alpha_v\beta_3$ and nonspecific sites blocked for two hours at 27°C. Soluble Fabs were prepared by isolating periplasmic fractions of cultures of *E. coli* strain MK30-3 (Boehringer Mannheim Co.) infected with the
- 10 Fab expressing M13 phage clones. Periplasm fractions were mixed with binding buffer 100 mM NaCl, 50 mM Tris pH 7.4, 2mM CaCl₂, 1 mM MgCl₂, 1 mM MnCl₂, 0.02% NaN₃, 1 mg/ml BSA and incubated with immobilized $\alpha_v\beta_3$ for two hours at 27°C. Plates were washed with binding buffer and bound
- 15 Fab detected with goat anti-murine kappa chain antibody conjugated to alkaline phosphatase. Four $\alpha_v\beta_3$ reactive clones were identified: muLM609M13 12, 29, 31 and 69. MuLM609M13 12 and 29 gave the strongest signals in the ELISA assay. DNA sequence analysis showed that clones
- 20 muLM609M13 12, 31 and 69 all had identical light chain sequence and confirmed the previously determined N-terminal amino acid sequence of purified LM609 light chain polypeptide. All four clones had identical V_H DNA sequence and also confirmed the previously determined
- 25 N-terminal amino acid sequence of purified LM609 heavy chain polypeptide.

To further characterize the binding activity of each clone, soluble Fab fractions were prepared from 50 ml cultures of *E. coli* strain MK30-3 infected with clones

12 and 29 and evaluated for binding to $\alpha_v\beta_3$ in a competitive ELISA with LM609 IgG. The results of this ELISA are shown in Figure 3. Clone muLM609M13 12 was found to inhibit LM609 IgG binding (at LM609 IgG concentrations of 1 ng/ml and 5 ng/ml) to $\alpha_v\beta_3$ in a concentration dependent manner at periplasm titers ranging from neat to 1:80. Clone muLM609M13 12 was plaque purified and both the V region heavy and light chain DNA sequences again determined. Complete DNA sequence of the final clone, muLM609M13 12-5, is shown in Figures 2A and 2B.

EXAMPLE II

Construction of LM609 Grafted Functional Antibody Fragments

15 This Example shows the construction of functional LM609 grafted antibody fragments in which only the CDRs have been transferred from the LM609 donor antibody to a human acceptor framework.

20 CDR grafting of LM609 to produce a functional antibody fragment was accomplished by the methods set forth below. These procedures are applicable for the CDR grafting of essentially any donor antibody where amino acid residues outside of the CDRs from the donor antibody are not desired in the final grafted product.

25 Briefly, the protein sequence of the LM609 antibody, was determined by cloning and sequencing the cDNA that encodes the variable regions of the heavy and

light chains as described in Example I. The CDRs from the LM609 donor antibody were identified and grafted into homologous human variable regions of a human acceptor framework. Identification of CDR regions were based on
5 the combination of definitions published by Kabat et al., and MacCallum et al.

The boundaries of the CDR regions have been cumulatively defined by the above two publications and are residues 30-35, 47-66 and 97-106 for CDRs 1, 2 and 3,
10 respectively, of the heavy chain variable region and residues 24-36, 46-56, and 89-97 for CDRs 1, 2 and 3, respectively, of the light chain variable region. Non-identical donor residues within these boundaries but outside of CDRs as defined by Kabat et al. were
15 identified and were not substituted into the acceptor framework. Instead, functional non-donor amino acid residues were identified and substituted for certain of these non-identical residues.

As described below, the only non-identical
20 residue outside of the CDRs as defined by Kabat et al. but within the CDRs as defined above is at position 49 of the LM609 light chain. To identify functional non-donor amino acids at this position, a library of nineteen antibodies was constructed that contained all non-donor
25 amino acids at position 49 and then screened for binding activity against $\alpha v \beta 3$.

Human immunoglobulin sequences were identified from the Brookhaven Protein Data Bank-Kabat Sequences of

Proteins of Immunological Interest database (release 5.0). Human framework sequences showing significant identity to the murine LM609 variable region gene sequences were selected for receiving the LM609 CDRs.

5 Human heavy chain variable region M72 'CL had 88% identity to frameworks 1, 2 and 3 of LM609 heavy chain and human light chain V region LS1 'CL had 79% identity to frameworks 1, 2 and 3 of LM609 light chain. With the exclusion of non-identical residues outside of the CDRs
10 as defined by Kabat et al. murine LM609 CDR sequences as defined by Kabat et al. and MacCallum et al. were grafted onto the human frameworks. Using this grafting scheme, the final grafted product does not contain any amino acid residues outside of the CDRs as defined by Kabat et al.
15 which are identical to an LM609 amino acid at the corresponding position (outside of residues: 31-35, 50-66 and 99-106 for CDRs 1, 2 and 3, respectively, of the heavy chain variable region and residues 24-34, 50-56, and 89-97 for CDRs 1, 2 and 3, respectively, of the light
20 chain variable region). Moreover, no intermediates are produced which contain an amino acid residue outside of the CDRs as defined by Kabat et al. which are identical to the LM609 amino acid at that position. The CDR grafting procedures are set forth below.

25 Full-length CDR grafted variable region genes were synthesized by PCR using long overlapping oligonucleotides. The heavy chain oligonucleotides map to the following nucleotide positions: V_H oligonucleotide 1 (V_H oligo1), nucleotides (nt) 1-84; (SEQ ID NO:9); V_H
30 oligo2, nt 70-153, (SEQ ID NO:10); V_H oligo3, nt 138-225

(SEQ ID NO:11); V_H oligo4, nt 211-291 (SEQ ID NO:12); V_H oligo5, nt 277-351 (SEQ ID NO:13).

The light chain variable region oligonucleotides were synthesized so as to contain the
5 CDR grafted variable region as well as a stop codon at position 49. The five oligonucleotides for the light chain LM609 grafted variable region are shown as SEQ ID NOS:14-18 where the second oligonucleotide in the series contains the stop codon at position 49 (SEQ ID NO:15).

10 All long oligonucleotides were gel purified. CDR grafting of the LM609 heavy chain variable region was constructed by mixing 5 overlapping oligonucleotides (SEQ ID NOS:9-13), at equimolar concentrations, in the presence of annealing PCR primers containing at least 18
15 nucleotide residues complementary to vector sequences for the efficient annealing of the amplified V region product to the single-stranded vector. The annealed mixture was fully converted to a double-stranded molecule with T4 DNA polymerase plus dNTPs and ligated with T4 ligase. The
20 mutagenesis reaction (1 μ l) was electroporated into *E. coli* strain DH10B (BRL), titered onto a lawn of XL-1 (Stratagene, Inc.) and incubated until plaques formed. Replica filter lifts were prepared and plaques containing V_H gene sequences were screened either by hybridization
25 with a digoxigenin-labeled oligonucleotide complementary to LM609 heavy chain CDR 2 sequences or reactivity with 7F11-alkaline phosphatase conjugate, a monoclonal antibody raised against the decapeptide sequence Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Ser (SEQ ID NO:23) appended

to the carboxy terminus of the vector CH₁ domain (Biosite, Inc., San Diego, CA).

Fifty clones that were double-positive were pooled and used to prepare uridinylated template for hybridization mutagenesis with the amplified CDR grafted LM609 V_L product constructed in a similar fashion using the five overlapping oligonucleotides shown as SEQ ID NOS:23-27. The mutagenesis reaction was electroporated into *E. coli* strain DH10B. Randomly picked clones were sequenced to identify a properly constructed template for construction of the non-donor library at position 49. This template was prepared as a uridinylated template and an oligonucleotide population of the following sequence was used for site directed mutagenesis.

GGGAACGATA-19aa-GATGAGAAGC

The sequence 19aa in the above primer (SEQ ID NO:24) represents the fact that this primer specifies a sequence population consisting of 19 different codon sequences that encode each of the 19 non-donor amino acids. These amino acids are those not found at position 49 of LM609 and include all amino acids except for Lys. Clones that resulted from this mutagenesis were picked and antibody expressed by these clones were prepared. These samples were then screened for binding to $\alpha\text{v}\beta 3$ in an ELISA assay. Clones having either Arg or Met amino acids in position 49 were functionally identified. The nucleotide and amino acid sequence of the LM609 grafted heavy chain variable region is shown in Figure 1A (SEQ ID NOS:1 and 2,

respectively). The nucleotide and amino acid sequence of the LM609 grafted light chain variable region is shown in Figure 1B (SEQ ID NOS:3 and 4, respectively).

Although the invention has been described with
5 reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific experiments detailed are only illustrative of the invention. It should be understood that various
10 modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.

200310.04506280

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Huse, William D.
- (ii) TITLE OF INVENTION: Anti-Alpha V Beta 3 Recombinant Human Antibodies, Nucleic Acids Encoding Same and Methods of Use
- (iii) NUMBER OF SEQUENCES: 24
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Campbell & Flores LLP
 - (B) STREET: 4370 La Jolla Village Drive, Suite 700
 - (C) CITY: San Diego
 - (D) STATE: California
 - (E) COUNTRY: United States
 - (F) ZIP: 92122
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Campbell, Cathryn A.
 - (B) REGISTRATION NUMBER: 31,815
 - (C) REFERENCE/DOCKET NUMBER: P-IX 2405
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (619) 535-9001
 - (B) TELEFAX: (619) 535-8949

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 351 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 1..351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

CAG	GTG	CAG	CTG	GTG	GAG	TCT	GGG	GGA	GGC	GTT	GTG	CAG	CCT	GGA	AGG	48
Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg	
1				5					10					15		
TCC	CTG	AGA	CTC	TCC	TGT	GCA	GCC	TCT	GGA	TTC	ACC	TTC	AGT	AGC	TAT	96
Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr	
				20				25					30			

GAC ATG TCT TGG GTT CGC CAG GCT CCG GGC AAG GGT CTG GAG TGG GTC	144
Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val	
35 40 45	
GCA AAA GTT AGT AGT GGT GGT GGT AGC ACC TAC TAT TTA GAC ACT GTG	192
Ala Lys Val Ser Ser Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val	
50 55 60	
CAG GGC CGA TTC ACC ATC TCC AGA GAC AAT AGT AAG AAC ACC CTA TAC	240
Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70 75 80	
CTG CAA ATG AAC TCT CTG AGA GCC GAG GAC ACA GCC GTG TAT TAC TGT	288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
GCA AGA CAT AAC TAC GGC AGT TTT GCT TAC TGG GGC CAA GGG ACT ACA	336
Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr	
100 105 110	
GTG ACT GTT TCT AGT	351
Val Thr Val Ser Ser	
115	

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 117 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg	
1 5 10 15	
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr	
20 25 30	
Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val	
35 40 45	
Ala Lys Val Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val	
50 55 60	
Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70 75 80	
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr	
100 105 110	
Val Thr Val Ser Ser	
115	

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 321 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..321

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GAG ATT GTG CTA ACT CAG TCT CCA GCC ACC CTG TCT CTC AGC CCA GGA	48
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly	
1 5 10 15	
GAA AGG GCG ACT CTT TCC TGC CAG GCC AGC CAA AGT ATT AGC AAC CAC	96
Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His	
20 25 30	
CTA CAC TGG TAT CAA CAA AGG CCT GGT CAA GCC CCA AGG CTT CTC ATC	144
Leu His Thr Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile	
35 40 45	
MKK TAT CGT TCC CAG TCC ATC TCT GGG ATC CCC GCC AGG TTC AGT GGC	192
Xaa Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly	
50 55 60	
AGT GGA TCA GGG ACA GAT TTC ACC CTC ACT ATC TCC AGT CTG GAG CCT	240
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro	
65 70 75 80	
GAA GAT TTT GCA GTC TAT TAC TGT CAA CAG AGT GGC AGC TGG CCT CAC	288
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Gly Ser Trp Pro His	
85 90 95	
ACG TTC GGA GGG GGG ACC AAG GTG GAA ATT AAG	321
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys	
100 105	

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly	
1 5 10 15	
Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His	
20 25 30	
Leu His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile	
35 40 45	

Xaa Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
 65 70 75 80
 Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Gly Ser Trp Pro His
 85 90 95
 Thr Phe Gly Gly Thr Lys Val Glu Ile Lys
 100 105

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 351 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..351

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC TTA GTG AAG CCT GGA AGG Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg 1 5 10 15	48
TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC GCT TTC AGT AGC TAT Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr 20 25 30	96
GAC ATG TCT TGG GTT CGC CAG ATT CCG GAG AAG AGG CTG GAG TGG GTC Asp Met Ser Trp Val Arg Gln Ile Pro Glu Lys Arg Leu Glu Trp Val 35 40 45	144
GCA AAA GTT AGT AGT GGT GGT AGC ACC TAC TAT TTA GAC ACT GTG Ala Lys Val Ser Ser Gly Gly Ser Thr Tyr Leu Asp Thr Val 50 55 60	192
CAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTA TAC Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80	240
CTG CAA ATG AGC AGT CTG AAC TCT GAG GAC ACA GCC ATG TAT TAC TGT Leu Gln Met Ser Ser Leu Asn Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95	288
GCA AGA CAT AAC TAC GGC AGT TTT GCT TAC TGG GGC CAA GGG ACT CTG Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu 100 105 110	336
GTC ACT GTC TCT GCA Val Thr Val Ser Ala 115	351

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 117 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg
 1 5 10 15
 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr
 20 25 30
 Asp Met Ser Trp Val Arg Gln Ile Pro Glu Lys Arg Leu Glu Trp Val
 35 40 45
 Ala Lys Val Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val
 50 55 60
 Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr
 65 70 75 80
 Leu Gln Met Ser Ser Leu Asn Ser Glu Asp Thr Ala Met Tyr Tyr Cys
 85 90 95
 Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu
 100 105 110
 Val Thr Val Ser Ala
 115

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 321 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..321

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

GAT ATT GTG CTA ACT CAG TCT CCA GCC ACC CTG TCT GTG ACA CCA GGA 48
 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
 1 5 10 15
 GAT AGC GTC AGT CTT TCC TGC CAG GCC AGC CAA AGT ATT AGC AAC CAC 96
 Asp Ser Val Ser Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His
 20 25 30
 CTA CAC TGG TAT CAA CAA AAA TCA CAT GAG TCT CCA AGG CTT CTC ATC 144
 Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
 35 40 45
 AAG TAT CGT TCC CAG TCC ATC TCT GGG ATC CCC TCC AGG TTC AGT GGC 192
 Lys Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60
 AGT GGA TCA GGG ACA GAT TTC GCT CTC AGT ATC AAC AGT GTG GAG ACT 240
 Ser Gly Ser Gly Thr Asp Phe Ala Leu Ser Ile Asn Ser Val Glu Thr
 65 70 75 80

GAA GAT TTT GGA ATG TAT TTC TGT CAA CAG AGT GGC AGC TGG CCT CAC 288
 Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Gly Ser Trp Pro His
 85 90 95

ACG TTC GGA GGG GGG ACC AAG CTG GAA ATT AAG 321
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 107 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly
 1 5 10 15
 Asp Ser Val Ser Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His
 20 25 30
 Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile
 35 40 45
 Lys Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly
 50 55 60
 Ser Gly Ser Gly Thr Asp Phe Ala Leu Ser Ile Asn Ser Val Glu Thr
 65 70 75 80
 Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Gly Ser Trp Pro His
 85 90 95
 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
 100 105

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

CAGGTGCAGC TGGTGGAGTC TGGGGGAGGC GTGTGCAGC CTGGAAGGTC CCTGAGACTC 60
 TCCTGTGCAG CCTCTGGATT CACC 84

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

AACITTTGCG ACCCACTCCA GACCTTGCC CGGAGCCTGG CGAACCCAAG ACATGTCATA 60
GCTACTGAAG GTGAATCCAG AGGC 84

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGGGTCGCAA AAGTTAGTAG TGGTGGTGGT AGCACCTACT ATTTAGACAC TGTGCAGGGC 60
CGATTACCA TCCTCAGAGA CAATAGT 87

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 81 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

TGCACAGTAA TACACGGCTG TGCCTCGGC TCTCAGAGAG TTCATTGCA GGTATAGGGT 60
GTTCTTACTA TTGTCCTGG A 81

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 75 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

GTGTATTACT GTCAAGACA TAACTACGGC AGTTTGTCTT ACTGGGGCCA AGGGACTACA 60
GTGACTGTTT CTAGT 75

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 87 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

GAGATTGTGC TAACTCAGTC TCCAGCCACC CTGTCTCTCA GCCCAGGAGA AAGGGCGACT 60
 CTTTCCTGCC AGGCCAGCCA AAGTATT 87

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 75 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

TTAGATGAGA AGCCTTGGGG CTTGACCAGG CCTTTGTTGA TACCAGTGTA GGTGTTGCT 60
 AATACTTTGG CTGGC 75

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 84 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCAAGGCTTC TCATCTAATA TCGTTCCAG TCCATCTCTG GGATCCCCGC CAGGTTCACT 60
 GGCAGTGGAT CAGGGACAGA TTTC 84

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 81 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GCTGCCACTC TGTTGACAGT AATAGACTGC AAAATCTTCA GGCTCCAGAC TGGAGATAGT 60
 GAGGGTGAAA TCTGTCCCTG A 81

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 57 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CAACAGAGTG GCAGCTGGCC TCACACGTTT GGAGGGGGGA CCAAGGTGGA AATTAAG 57

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GCCCAACCAG CCATGGCCGA TATTGTGCTA ACTCAG

36

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

ACAGTTGGTG CAGCATCAGC

20

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

ACCCCTGTGG CAAAAGCCGA AGTGCAGCTG GTGGAG

36

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GATGGGGGTG TCGTTTGGC

20

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GCTACTGAAG GCGAATCCAG AG

22

(2) INFORMATION FOR SEQ ID NO:24:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 23 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: misc_feature
- (B) LOCATION: 11..13
- (D) OTHER INFORMATION: /note= "NNN" represents a codon specifying any amino acid other than Lys."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

GGGAACGATA NNNGATGAGA AGC

23

What is claimed is:

1. A LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$, comprising at least one LM609 grafted heavy chain polypeptide comprising substantially the same variable region amino acid
5 sequence as that shown in Figure 1A (SEQ ID NO:2) and at least one LM609 grafted light chain polypeptide comprising substantially the same variable region amino acid sequence as that shown in Figure 1B (SEQ ID NO:4) or a functional fragment thereof.
- 10 2. The LM609 grafted antibody of claim 1, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.
3. A nucleic acid encoding a LM609 grafted heavy chain polypeptide comprising substantially the same
15 LM609 grafted heavy chain variable region nucleotide sequences as that shown in Figure 1A (SEQ ID NO:1) or a fragment thereof.
4. The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding
20 substantially the same nucleotide sequence as the variable region of said LM609 grafted heavy chain polypeptide (SEQ ID NO:1).

5. The nucleic acid of claim 3, wherein said fragment further comprises a nucleic acid encoding substantially the same nucleotide sequence as a CDR of said LM609 grafted heavy chain polypeptide.

5 6. A nucleic acid encoding a LM609 grafted light chain polypeptide comprising substantially the same LM609 grafted light chain variable region nucleotide sequences as that shown in Figure 1B (SEQ ID NO:3) or a fragment thereof.

10 7. The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding substantially the same nucleotide sequence as the variable region of said LM609 grafted light chain polypeptide (SEQ ID NO:3).

15 8. The nucleic acid of claim 6, wherein said fragment further comprises a nucleic acid encoding substantially the same nucleotide sequence as a CDR of said LM609 grafted light chain polypeptide.

20 9. A nucleic acid encoding a LM609 grafted antibody heavy chain polypeptide comprising a nucleotide sequence encoding substantially the same LM609 grafted heavy chain variable region amino acid sequence as that shown in Figure 1A (SEQ ID NO:2) or fragment thereof.

10. The nucleic acid of claim 9, wherein said fragment further comprises a nucleic acid encoding substantially the same heavy chain variable region amino acid sequence of said LM609 grafted heavy chain amino acid sequence (SEQ ID NO:2).

11. The nucleic acid of claim 9, wherein said fragment further comprises a nucleic acid encoding substantially the same heavy chain CDR amino acid sequence of said LM609 grafted heavy chain amino acid sequence.

12. A nucleic acid encoding a LM609 grafted antibody light chain polypeptide comprising a nucleotide sequence encoding substantially the same LM609 grafted light chain variable region amino acid sequence as that shown in Figure 1B (SEQ ID NO:4) or fragment thereof.

13. The nucleic acid of claim 12, wherein said fragment further comprises a nucleic acid encoding substantially the same light chain variable region amino acid sequence of said LM609 grafted light chain amino acid sequence (SEQ ID NO:4).

14. The nucleic acid of claim 12, wherein said fragment further comprises a nucleic acid encoding substantially the same light chain CDR amino acid sequence of said LM609 grafted light chain amino acid sequence.

15. A LM609 grafted heavy chain polypeptide comprising substantially the same variable region amino acid sequence as that shown in Figure 1A (SEQ ID NO:2) or functional fragment thereof.

5 16. The LM609 grafted heavy chain polypeptide of claim 15, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

17. A LM609 grafted light chain polypeptide comprising substantially the same variable region amino acid sequence as that shown in Figure 7 (SEQ ID NO:4) or a functional fragment thereof.

18. The LM609 grafted light chain polypeptide of claim 17, wherein said functional fragment comprises a variable chain polypeptide or a CDR polypeptide.

15 19. A method of inhibiting a function of $\alpha_v\beta_3$, comprising contacting $\alpha_v\beta_3$ with a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding of LM609 grafted antibodies to $\alpha_v\beta_3$.

20 20. The method of claim 19, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

21. The method of claim 19, wherein said function of $\alpha_v\beta_3$ is binding of $\alpha_v\beta_3$ to a ligand.

22. The method of claim 19, wherein said function of $\alpha_v\beta_3$ is integrin mediated signal transduction.

23. A method of treating an $\alpha_v\beta_3$ -mediated disease comprising administering an effective amount of a LM609 grafted antibody or a functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$.

24. The method of claim 23, wherein said functional fragment is selected from the group consisting of Fv, Fab, F(ab)₂ and scFV.

25. The method of claim 23, wherein said $\alpha_v\beta_3$ -mediated disease is angiogenesis or restenosis.

ABSTRACT OF THE INVENTION

The invention provides a LM609 grafted antibody exhibiting selective binding affinity to $\alpha_v\beta_3$. The LM609 grafted antibody consists of at least one LM609 CDR grafted heavy chain polypeptide and at least one LM609 CDR grafted light chain polypeptide or functional fragment thereof. Nucleic acids encoding LM609 grafted heavy and light chains as well as nucleic acids encoding the parental non-human antibody LM609 are additionally provided. Functional fragments of such encoding nucleic acids are similarly provided. The invention also provides a method of inhibiting a function of $\alpha_v\beta_3$. The method consists of contacting $\alpha_v\beta_3$ with a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$. Finally, the invention provides for a method of treating an $\alpha_v\beta_3$ -mediated disease. The method consists of administering an effective amount of a LM609 grafted antibody or functional fragment thereof under conditions which allow binding to $\alpha_v\beta_3$.

Figure 1a

CAG GTG CAG CTG GTG GAG TCT GGG GGA GGC GTT GTG CAG CCT GGA AGG	48
Gln Val Gln Leu Val Glu Ser Gly Gly Val Val Gln Pro Gly Arg	
1 5 10 15	
TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT	96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr	
20 25 30	
GAC ATG TCT TGG GTT CGC CAG GCT CCG GGC AAG GGT CTG GAG TGG GTC	144
Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val	
35 40 45	
GCA AAA GTT AGT AGT GGT GGT GGT AGC ACC TAC TAT TTA GAC ACT GTG	192
Ala Lys Val Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val	
50 55 60	
CAG GGC CGA TTC ACC ATC TCC AGA GAC AAT AGT AAG AAC ACC CTA TAC	240
Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70 75 80	
CTG CAA ATG AAC TCT CTG AGA GCC GAG GAC ACA GCC GTG TAT TAC TGT	288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
GCA AGA CAT AAC TAC GGC AGT TTT GCT TAC TGG GGC CAA GGG ACT ACA	336
Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Thr	
100 105 110	
GTG ACT GTT TCT AGT	351
Val Thr Val Ser Ser	
115	

Figure 1b

GAG ATT GTG CTA ACT CAG TCT CCA GCC ACC CTG TCT CTC AGC CCA GGA Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15	48
GAA AGG GCG ACT CTT TCC TGC CAG GCC AGC CAA AGT ATT AGC AAC CAC Glu Arg Ala Thr Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His 20 25 30	96
CTA CAC TGG TAT CAA CAA AGG CCT GGT CAA GCC CCA AGG CTT CTC ATC Leu His Trp Tyr Gln Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45	144
CGT/ATG TAT CGT TCC CAG TCC ATC TCT GGG ATC CCC GCC AGG TTC AGT GGC Arg/Met Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60	192
AGT GGA TCA GGG ACA GAT TTC ACC CTC ACT ATC TCC AGT CTG GAG CCT Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80	240
GAA GAT TTT GCA GTC TAT TAC TGT CAA CAG AGT GGC AGC TGG CCT CAC Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Gly Ser Trp Pro His 85 90 95	288
ACG TTC GGA GGG GGG ACC AAG GTG GAA ATT AAG Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 105	321

Figure 2a

GAA GTG CAG CTG GTG GAG TCT GGG GGA GGC TTA GTG AAG CCT GGA AGG	48
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Arg	
1 5 10 15	
TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC GCT TTC AGT AGC TAT	96
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ala Phe Ser Ser Tyr	
20 25 30	
GAC ATG TCT TGG GTT CGC CAG ATT CCG GAG AAG AGG CTG GAG TGG GTC	144
Asp Met Ser Trp Val Arg Gln Ile Pro Glu Lys Arg Leu Glu Trp Val	
35 40 45	
GCA AAA GTT AGT AGT GGT GGT GGT AGC ACC TAC TAT TTA GAC ACT GTG	192
Ala Lys Val Ser Ser Gly Gly Gly Ser Thr Tyr Tyr Leu Asp Thr Val	
50 55 60	
CAG GGC CGA TTC ACC ATC TCC AGA GAC AAT GCC AAG AAC ACC CTA TAC	240
Gln Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr	
65 70 75 80	
CTG CAA ATG AGC AGT CTG AAC TCT GAG GAC ACA GCC ATG TAT TAC TGT	288
Leu Gln Met Ser Ser Leu Asn Ser Glu Asp Thr Ala Met Tyr Tyr Cys	
85 90 95	
GCA AGA CAT AAC TAC GGC AGT TTT GCT TAC TGG GGC CAA GGG ACT CTG	336
Ala Arg His Asn Tyr Gly Ser Phe Ala Tyr Trp Gly Gln Gly Thr Leu	
100 105 110	
GTC ACT GTC TCT GCA	351
Val Thr Val Ser Ala	
115	

Figure 2b

GAT ATT GTG CTA ACT CAG TCT CCA GCC ACC CTG TCT GTG ACA CCA GGA Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly	48
1 5 10 15	
GAT AGC GTC AGT CTT TCC TGC CAG GCC AGC CAA AGT ATT AGC AAC CAC Asp Ser Val Ser Leu Ser Cys Gln Ala Ser Gln Ser Ile Ser Asn His	96
20 25 30	
CTA CAC TGG TAT CAA CAA AAA TCA CAT GAG TCT CCA AGG CTT CTC ATC Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile	144
35 40 45	
AAG TAT CGT TCC CAG TCC ATC TCT GGG ATC CCC TCC AGG TTC AGT GGC Lys Tyr Arg Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly	192
50 55 60	
AGT GGA TCA GGG ACA GAT TTC GCT CTC AGT ATC AAC AGT GTG GAG ACT Ser Gly Ser Gly Thr Asp Phe Ala Leu Ser Ile Asn Ser Val Glu Thr	240
65 70 75 80	
GAA GAT TTT GGA ATG TAT TTC TGT CAA CAG AGT GGC AGC TGG CCT CAC Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Gly Ser Trp Pro His	288
85 90 95	
ACG TTC GGA GGG GGG ACC AAG CTG GAA ATT AAG Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys	321
100 105	

Huse and Glaser
p-IX 2405

LM609 Competition Assay




Figure 3



Docket No. P-IX 2405

Applicant: Patentees: William D. Huse

Serial or Patent No.: 08/790,540

Filed or Issued: January 30, 1997

For: ANTI- α , β , RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE

VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS (37 CFR 1.9(F) AND 1.27(C))

SMALL BUSINESS CONCERN

I hereby declare that I am

☐ the owner of the small business concern identified below:

☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF SMALL BUSINESS CONCERN: IXSYS, INCORPORATED
ADDRESS OF SMALL BUSINESS CONCERN: 3550 Dunhill Road
San Diego, CA 92121

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled ANTI- α , β , RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE by inventor(s) William D. Huse as described in:

☐ the specification filed herewith
☒ application serial no. 08/790,540, filed January 30, 1997
☐ patent no. _____, issued _____

If the rights held by the above identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

Applicants or Patentees: **William D. Huse**

Serial or Patent No.: **08/790,540**

Filed or Issued: **January 30, 1997**

For: **ANTI- $\alpha_v\beta_3$, RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE**

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME: _____

ADDRESS: _____

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: William D. Huse, M.D., Ph.D.
TITLE IN ORGANIZATION: Chief Scientific Officer
ADDRESS OF PERSON SIGNING: 3550 Dunhill Street
San Diego, CA 92121

SIGNATURE: W D Huse

DATE: 3/31/97



DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION

As the below-named inventor, I hereby declare that:

My residence, post office address and citizenship
are as stated below next to my name.

I believe I am the original, first and sole inventor
of the subject matter which is claimed and for which a patent
is sought on the invention entitled ANTI- $\alpha_v\beta_3$ RECOMBINANT HUMAN
ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE,
the specification of which

_____ is attached hereto as Attorney Docket No.
_____).

X was filed on January 30, 1997 (Attorney
Docket No. P-IX 2405) as Application Serial No.
08/790,540 and was amended on (or amended
through) _____.
(if applicable)

I hereby state that I have reviewed and understand
the contents of the above-identified specification, including
the claims, as amended by any amendment(s) referred to above.

I acknowledge the duty to disclose information which
is material to the examination of this application in
accordance with Title 37, Code of Federal Regulations, Sec.
1.56(a).

2025 JUN 2 1997

William D. Huse
Serial No.: 08/790,540
Filed: January 30, 1997
Page 2

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:


CATHRYN CAMPBELL, Registration No. 31,815; SUSAN M. PERKINS, Registration No. 36,405; RICHARD J. IMBRA, Registration No. 37,643; PAUL C. STEINHARDT, Registration No. 30,806; GREGORY R. HOOK, Registration No. 38,701; DAVID SPOLTER, Registration No. 36,933; DAVID A. GAY, Registration No. 39,200; CALVIN A. FAN, Registration No. 38,444; JANE E.R. POTTER, Registration No. 33,332; DAVID R. PRESTON, Registration No. 38,710; ROBERT T. RAMOS, Registration No. 37,915; and CHARLENE A. LAUNER, Registration No. 33,035. Direct all telephone calls to Cathryn Campbell at telephone no. (619) 535-9001.

William D. Huse
Serial No.: 08/790,540
Filed: January 30, 1997
Page 3

Address all correspondence to:

CATHRYN CAMPBELL
CAMPBELL & FLORES LLP
4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

Full name of inventor: ¹⁻⁰⁰ William D. Huse

Inventor's signature: 

Date: 3/31/97

Residence: Del Mar, California

Citizenship: United States 

Post Office Address: 471 Avenida Primavera
Del Mar, California 92014

2025 MAR 31 PM 3:55